IXALTIS Announces the Completion of its Capital Increase

ARCHAMPS TECHNOPOLE and TOULOUSE, France, May 22, 2017 /PRNewswire/ --

The start-up specializing in developing treatments for Urogenital Disorders completed the subscription of the second tranche of round A capital increase.  

To view the Multimedia News Release, please click:

https://www.multivu.com/players/uk/8106251-ixaltis-completion-capital-increase

Less than a year after completion of its first tranche of investment (4,5MEUR in May 2016), and per its projected calendar, IXALTIS obtained the release of the second tranche of investment. These are additional 3,5MEUR that IXALTIS just received from its investors (IRDInov, IXO Private Equity, Principia SGR, Pierre-Olivier Goineau and Sofimac Partners), bringing the total money raised to 8 million Euros.

The delivery of this second tranche of investment was subject to achievement of several scientific and commercial milestones and has been deemed completed upon the exercise of second tranche warrants by the investors.

This continued commitment from the financial partners concretizes the confidence given to the IXALTIS team for the conduct of the clinical program and the scientific studies.

This allows the company to pursue the development of its compounds, and most of all its Phase II clinical trial on Litoxetine which has just begun and will be including 240 women suffering from urinary incontinence. This study, overseen by Professor François Haab, surgeon urologist and medical expert, has already collected the inclusion of several patients from 18 to 75 years old, in 25 centres and 6 countries in Europe and Canada.

The stakes are high, Litoxetine could improve the condition of many patients around the world affected by this disease with a severe impact on their quality of life and ability to work.

IXALTIS is start-up company specialized in genitourinary and renal diseases. It has acquired from Sanofi the rights to three molecules, including Litoxetine IXA-001, and completed the round A of financing in 2016. Litoxetine is a highly selective serotonin (5-HT) reuptake inhibitor and a multifunctional serotonin agonist-antagonist (MSAA) under development for mixed urinary incontinence. A phase 2 dose finding study is ongoing.  

Mixed Urinary Incontinence (MUI) is a seriously debilitating disease that affects about 400 million people worldwide and up to 50% of the women over 50 years of age: no medical treatment is currently approved for this disease.  

More information on: http://www.ixaltis.com

(Photo: http://mma.prnewswire.com/media/512318/IXALTIS_Completion_Capital.jpg )



Photo:
http://mma.prnewswire.com/media/512318/IXALTIS_Completion_Capital.jpg






Video:
https://www.multivu.com/players/uk/8106251-ixaltis-completion-capital-increase




CONTACT: Press office IXALTIS MEDIACOM Consulting Agency +33-450-431-515 / +41-22-342-10-10

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234